Matches in Nanopublications for { ?s ?p "[We estimated the cumulative incidence of first disease-free survival (DFS) events in the CNS versus other sites by competing risks analysis in patients with HER2-positive early breast cancer who had been randomly assigned to receive 1 year of trastuzumab or to observation in the HERA trial after a median follow-up of 4 years (IQR 3�5-4�8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_assertion description "[We estimated the cumulative incidence of first disease-free survival (DFS) events in the CNS versus other sites by competing risks analysis in patients with HER2-positive early breast cancer who had been randomly assigned to receive 1 year of trastuzumab or to observation in the HERA trial after a median follow-up of 4 years (IQR 3�5-4�8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.
- NP1053427.RAc9yCnRFaSV1prIa7bsU7Cg8K1qwc__z4irLeOwoYsec130_assertion description "[We estimated the cumulative incidence of first disease-free survival (DFS) events in the CNS versus other sites by competing risks analysis in patients with HER2-positive early breast cancer who had been randomly assigned to receive 1 year of trastuzumab or to observation in the HERA trial after a median follow-up of 4 years (IQR 3�5-4�8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053427.RAc9yCnRFaSV1prIa7bsU7Cg8K1qwc__z4irLeOwoYsec130_provenance.
- NP882938.RAh0Whwr3g43KECsq6ZBigRzB7YgqImB6h5qvsuqjf07Q130_assertion description "[We estimated the cumulative incidence of first disease-free survival (DFS) events in the CNS versus other sites by competing risks analysis in patients with HER2-positive early breast cancer who had been randomly assigned to receive 1 year of trastuzumab or to observation in the HERA trial after a median follow-up of 4 years (IQR 3�5-4�8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP882938.RAh0Whwr3g43KECsq6ZBigRzB7YgqImB6h5qvsuqjf07Q130_provenance.
- NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_assertion description "[We estimated the cumulative incidence of first disease-free survival (DFS) events in the CNS versus other sites by competing risks analysis in patients with HER2-positive early breast cancer who had been randomly assigned to receive 1 year of trastuzumab or to observation in the HERA trial after a median follow-up of 4 years (IQR 3�5-4�8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP882945.RAsB26GvqatI-wMTFSHIB20IW6GcFa1qcB5Xfsq5jdroU130_provenance.
- NP1053428.RAto71XYhSzVk_3hqKCIE0HGTAChKBLUnRmL9bK_A4CkY130_assertion description "[We estimated the cumulative incidence of first disease-free survival (DFS) events in the CNS versus other sites by competing risks analysis in patients with HER2-positive early breast cancer who had been randomly assigned to receive 1 year of trastuzumab or to observation in the HERA trial after a median follow-up of 4 years (IQR 3�5-4�8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053428.RAto71XYhSzVk_3hqKCIE0HGTAChKBLUnRmL9bK_A4CkY130_provenance.